← Back to all trials
Not Yet Recruiting
NCT07807969
An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
Conditions: Geographic Atrophy
Sex: All
Ages: 50 Years – N/A
Healthy volunteers: No
Phase: PHASE3
Enrollment: 605
Sponsor: Annexon, Inc.
Location: Retina Group of Florida Sarasota Florida
Summary
The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.
Eligibility Criteria
Inclusion Criteria:
* Participants with a diagnosis of dry AMD with GA who completed the Phase 3 ARCHER II study (NCT06510816) and who had not permanently ceased receiving the assigned masked treatment (IVT or Sham administration) at/before the ARCHER II Month 24 Visit.
Exclusion Criteria:
* Any event or condition arising during the ARCHER II study that would put the participant in danger or lead to undue harm by participating in this OLE study.
Source: ClinicalTrials.gov (NCT07807969). StuddyBuddy aggregates publicly available trial information.
